7月2日，Moderna盘中上涨5.72%，报77.405美元/股，成交额1.2亿美元。消息面上，公司近期多重利好持续推动股价走高。
6月25日Moderna举办科学日活动，首次披露体内CAR-T项目mRNA-6007，计划针对B细胞介导的自身免疫疾病于明年进入临床，同时展示肿瘤疫苗、癌症预防疫苗及AI研发平台等多条管线，市场对其向平台型生物药企估值切换的预期持续升温。此外，其季节性流感疫苗mRNA-1010此前获FDA咨询委员会9-0一致支持，最终审批决定预计8月初做出。受上述进展鼓舞，Piper Sandler将目标价上调至77美元，杰富瑞上调至53美元。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.